CPHI Webinar Series
Chiral Resolution by Salt/Cocrystal Formation
What will this webinar address?
Most of the drug molecules are chiral compounds with enantiomers. Each enantiomer may show significant differences in biological activities, such as pharmacodynamics, pharmacokinetics and toxicity. It is therefore recommended to market chiral drugs containing only the desired enantiomer. It is thus critical to develop a production process that leads to enantiopure dug substance. In this context, chiral resolution has become a crucial step in pharmaceutical development and crystallization-based resolutions are widely utilized to produce enantiopure drug substance of high purity. This presentation will review the concept of conglomerate, racemic compound and solid solution as well as how to differentiate them using phase diagrams and analytical techniques. It will discuss chiral resolution methods though salt and cocrystal formation followed by crystallization using a couple of case studies. One case study was to identify a cocrystal conglomerate followed by development of a chiral resolution process based on preferred crystallization. The other case study is to perform classic chiral resolution by diastereomeric salt formation which is considered one of the most effective methods for production of chirally pure drugs at large scale.
- Understand why classical resolution by salt formation is often considered as one of the most efficient methods to produce enantiopure pharmaceuticals on a large scale
- strategically design a rational approach to a solid form screening study
- Optimize a crystallization process to be scaled up to various scales
Dr. Shanming Kuang is currently the Head of Center for Pharma Crystallization at Porton Shanghai and Executive Director of Crystallization R&D at J-Star Research Inc. Shanming obtained his PhD in physical chemistry from the Chinese University of Hong Kong. After a postdoc at Purdue University, Shanming spent more than 20 years in pharma industry with BMS, Roche, GSK, Crystal Pharmatech and, most recently, J-Star Research Inc (now Porton USA). His tenure involves managing Solid State Chemistry Teams focusing on solid form screening and selection, crystallization process development and pre-formulation. His teams were integral in understanding drug candidate developability and ensuring projects were minimally impacted by solid-state property issues. Shanming has extensive experience in developability assessment for more than 400 small molecule drug candidates and has published more than 60 peered reviewed papers and patent applications.
This webinar is brought to you by
4pm CET / 10am EST
Get the latest from CPHI in your inbox every week.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
Generate high-quality, engaged leads for your business, all year round
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
Your company’s profile boosted at all participating CPHI events
An easy-to-use platform with a detailed dashboard showing your leads and performance